Tirzepatide API (CAS 2023788-19-2) | High-Purity SR-Peptides Manufacturer
Tirzepatide API (CAS 2023788-19-2) | High-Purity SR-Peptides Manufacturer
Tirzepatide API,Tirzepatide peptide powder,CAS 2023788-19-2,Dual GIP/GLP-1 agonist,SPPS peptide synthesis,SR-Peptides,Tirzepatide raw material manufacturer
Premium Tirzepatide API (CAS 2023788-19-2) with ≥99% HPLC purity. As a dedicated raw material manufacturer, we supply high-quality SR-Peptides for R&D and pharmaceutical formulation. Request COA
Send Inquiry
Description
Tirzepatide API (Lyophilized Powder)
World's First Dual GIP/GLP-1 Receptor Agonist | CAS: 2023788-19-2
B2B RAW MATERIAL SUPPLY: Shaanxi Sunrise Pharmaceutical Co., Ltd. supplies high-purity API for R&D, generic drug development, and pharmaceutical compounding only. Not for direct clinical use.
Storage Protocol:
• Unopened: -20°C ± 5°C (Frozen, dark, dry for 24-36 months).
• Transport/Short-term: 2-8°C refrigeration validated.
• Packaging: Sterile glass vials (2mL/5mL) with rubber stoppers and Alu-plastic seals.
• Unopened: -20°C ± 5°C (Frozen, dark, dry for 24-36 months).
• Transport/Short-term: 2-8°C refrigeration validated.
• Packaging: Sterile glass vials (2mL/5mL) with rubber stoppers and Alu-plastic seals.
Product Specifications
| Product Name | Tirzepatide / Tilpotide |
| CAS Number | 2023788-19-2 |
| Purity (Specification) | ≥ 99.0% (HPLC) |
| Active Structure | 39 Amino Acids + C20 Fatty Acid Chain |
| Molecular Formula | C225H348N50O68 |
| Molecular Weight | 4813.5 Da |
| Appearance | White to off-white freeze-dried powder / sponge-like solid |
| Synthesis Method | Solid-Phase Peptide Synthesis (SPPS) |
Mechanism of Action (MOA) Overview
The Enteropancreatin Synergy: Tirzepatide is a groundbreaking, once-weekly novel dual-channel agonist. It simultaneously targets the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Both GLP-1 and GIP are enteropancreatins secreted by the human gastrointestinal mucosa. While GLP-1 binds to pancreatic islet cells to stimulate insulin secretion, delay gastric emptying, and suppress appetite, the GIP component acts synergistically to inhibit gastric acid/pepsin secretion and further amplify insulin release. This dual-action mechanism significantly outpaces leading single-target GLP-1 drugs (such as Semaglutide) in comprehensive metabolic regulation.
Core R&D and Manufacturing Advantages
1. Dual Target Innovation
As the world's first GIP/GLP-1 receptor dual agonist API, it offers a revolutionary mechanism that produces synergistic hypoglycemic and weight-regulating effects, providing a superior foundation for next-generation drug formulations.
2. High Biological Activity
Demonstrates significant efficacy and high potency in assay testing, driven by our meticulous SPPS synthesis method that preserves the exact 39-amino acid sequence and C20 lipid chain integrity.
3. Long-Term Formulation Potential
Designed for long-term convenience in downstream formulations, supporting the development of stable, once-weekly administration profiles for chronic metabolic management.
Downstream Formulation Targets (Applications)
Our high-purity Tirzepatide API is strictly supplied for formulation R&D, pilot manufacturing, and generic drug development targeting:
Metabolic Therapeutics
Type 2 Diabetes (T2D) formulation development.
Obesity and severe overweight management drug design.
Research targeting the improvement of metabolic indicators (blood lipids, blood pressure, fatty liver).
Cardiovascular & Academic Research
Development of formulations aimed at reducing cardiovascular risk complications.
In-vitro and in-vivo scientific research on enteropancreatin pathways.
Exploration of potential expanded clinical indications (currently under global development).